University of Iowa Research Foundation

Roche Diagnostics Gmbh

F. Hoffmann-la Roche Ag

Thad Sharp

Brad A Amendt

Aliasger Karimjee Salem

Liu Hong

Stephen Gordon Will

Lin Wu

Satheesh Elangovan

Gustavo Avila Ortiz

Rachel Langland

The invention provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) transfecting the de-differentiated cell with an expression cassette comprising a promoter operably linked to a nucleic acid encoding a conversion agent to form a re-programmed differentiated cell. The invention also provides in certain embodiments, a method of generating a re-programmed differentiated epithelial cell comprising (a) contacting a non-stem somatic cell obtained from a subject with an effective amount of a de-differentiation agent to form a de-differentiated cell, and (b) contacting the de-differentiated cell with a conversion agent to form a re-programmed differentiated cell. The invention provides in certain embodiments, re-programmed differentiated epithelial cells, and methods of using these re-programmed differentiated epithelial cells to repair or re-generate tissue in vivo.

Methods to generate epithelial cells

In certain embodiments, the present invention provides the use of microRNA (miR)-200a to inhibit ossification and bone formation.

MicroRNA-200 based approaches for modulating bone formation inhibition and bone regeneration

Compositions and methods to prevent, inhibit or treat aveolar or periodontal bone loss, enhance bone regeneration, prevent, inhibit or treat peri-implantitis or periodontitis, e.g., periodontitis or peri-implantitis associated with bone loss, or to prevent, inhibit or treat osteoarthritis are provided.

Methods to prevent or treat periodontitis or peri-implantitis

In certain embodiments, the present invention provides the use of microRNA (miR)-200a and/or miR-200c to inhibit ossification and bone formation. In certain embodiments, the present invention provides the use of miR-200a inhibitor to stimulate bone regeneration.

Growing community of inventors

Iowa City, IA, United States of America

Thad Sharp